

**Michigan Department of Health and Human Services**  
**Questions about the MCO Common Formulary**  
**Stakeholder Meeting – October 24, 2016**

1.	Are each of the plans going to have the same PA length of approval?	<i>The PA Duration of Approval is identified in the PA Criteria document found at <a href="http://Michigan.gov/MCOPharmacy">Michigan.gov/MCOPharmacy</a>. Plans are allowed to be less restrictive.</i>
2.	Will the MCO Common Formulary Workgroup review coverage for head lice to verify whether there is a gap in coverage?	<i>The products in this drug class are scheduled for annual review by the workgroup and feedback from the October 24<sup>th</sup> Stakeholder meeting will be shared with the workgroup at that time.</i>
3.	When did the Grandfather process start?	<i>Plans chose to stagger the implementation process for the benefit of providers. That way it wasn't necessary for providers to get PAs for all of their patients at the same time. It was required that the implementation process was completed by September 30<sup>th</sup>. The grandfather date was determined based on the individual plans' implementation.</i>
4.	How will updates to the formulary be communicated?	<i>The updated formulary will be posted after completion of the approval process following the MCO Common Formulary Workgroup meetings. Within the first pages of the updated formulary is a formulary change listing.</i>
5.	Are there any cancer treatment drugs currently carved out?	<i>The 2 classes of cancer treatment drugs currently carved out are Antineoplastic Systemic Enzyme Inhibitors and Antineoplastic – MEK1 and MEK2 Kinase Inhibitors.</i>
6.	How will drug manufacturers present clinical information about drugs to the plans?	<i>There is no change. Drug manufacturers will continue to use the same process as prior to the MCO Common Formulary implementation. The Health Plans still have their own P &amp; T Committees. This information should still be forwarded to the plans for review with their committees. The plans will then bring the information to the MCO Common Formulary Workgroup.</i>
7.	How will Carved-Out drugs be identified, other than only saying "Not Covered"?	<i>MDHHS will be surveying the Health Plans now that they have implemented the Common Formulary to verify their messaging.</i>
8.	Is the FFS PA Criteria the same as the published MCO Common Formulary PA Criteria?	<i>No the criteria may differ.</i>
9.	Is a drug that is listed on the Michigan Pharmaceutical Product List (MPPL) automatically covered on the MCO Common Formulary?	<i>No, If a drug is on the MPPL found at <a href="http://Michigan.fhsc.com">Michigan.fhsc.com</a> &gt;&gt; <b>Providers &gt;&gt; Drug Information &gt;&gt; MPPL and Coverage Information</b>, but not covered on the MCO Common Formulary, the Health Plans must have a means to cover that drug through a non-formulary prior authorization process. Refer to the second page of the Medicaid Health Plan Common Formulary found at <a href="http://Michigan.gov/MCOPharmacy">Michigan.gov/MCOPharmacy</a>.</i>
10.	Can plans cover a drug before it is on the MPPL?	<i>Both FFS and Michigan Medicaid Health Plans will not approve a drug prior to being on the market for 6 months. Due to the ability to be less restrictive, plans could choose to cover a drug prior to it being put on the MPPL.</i>
11.	Where can someone sign up for Public Comment notification?	<i>If you would like to receive the quarterly Public Comment notices please subscribe to the Medicaid ListServ. The subscription instructions are found here: <a href="http://www.michigan.gov/documents/LISTSERV_127789_7.pdf">http://www.michigan.gov/documents/LISTSERV_127789_7.pdf</a>. This subscription-based e-mail service notifies subscribers of important news relative to the Michigan Medicaid Program, including Public Comment notices.</i>

12.	<b>Can you please tell me how Epilepsy drugs are going to be treated under the common formulary? Will the carve-out status change?</b>	<i>Please refer to the first page of the MCO Common Formulary for Drugs Reimbursed through Fee-For-Service Benefit (Carve-Out). Carve-out drugs, including Epilepsy drugs will remain carved out. Any proposed changes will require advanced legislative notice by the Department.</i>
13.	<b>What is the workgroup review schedule in order for the public to provide comment? What is the best method to provide comment?</b>	<i>The MCO Common Formulary Workgroup review schedule piggybacks off of the FFS P &amp; T Committee quarterly meetings. The quarterly Public Comment period will be posted on the MCO Common Formulary webpage at <b>Michigan.gov/MCOPharmacy</b>.</i>
14.	<b>Synagis is listed on the common formulary, so does it fall under common formulary (pharmacy benefit) or medical benefit?</b>	<i>Synagis is currently listed as a pharmacy benefit on the MCO Common Formulary. In addition plans may also cover Synagis as a medical benefit.</i>
15.	<b>Are oncology medicines both oral and infused carved out of common formulary?</b>	<i>A very limited number of oncology products are carved out. Please refer to the MCO Common Formulary for covered oncology products. Oral versus infused is not the underlying determinate for whether a product is carved out.</i>
16.	<b>When is the next meeting?</b>	<i>The Department committed to holding a Stakeholder meeting at least annually with quarterly Public Comment periods. Notice will be provided on the Michigan Medicaid Health Plan Pharmacy Benefit website found at <b>URL Michigan.gov/MCOPharmacy</b></i>